Journal of Peking University (Health Sciences) ›› 2020, Vol. 52 ›› Issue (3): 420-424. doi: 10.19723/j.issn.1671-167X.2020.03.004

Previous Articles     Next Articles

Risks factors for death among COVID-19 patients combined with hypertension, coronary heart disease or diabetes

Hang YANG1,Lin-cheng YANG2,Rui-tao ZHANG2,Yun-peng LING1,(),Qing-gang GE3,()   

  1. 1. Department of Cardiac Surgery
    2. Department of Cardiology
    3. Department of Intensive Care Unit, Peking University Third Hospital, Beijing 100191, China
  • Received:2020-04-13 Online:2020-06-18 Published:2020-06-30
  • Contact: Yun-peng LING,Qing-gang GE E-mail:micsling@163.com;qingganggelin@126.com

RICH HTML

  

Abstract:

Objective: The pathogenesis of myocardial injury upon corona virus disease 2019 (COVID-19) infection remain unknown,evidence of impact on outcome is insufficient, therefore, we aim to investigate the risk factors for death among COVID-19 patients combined with hypertension, coronary heart disease or diabetes in this study.Methods: This was a single-centered, retrospective, observational study. Patients of Sino-French Eco-City section of Tongji Hospital, Wuhan, China attended by Peking University Supporting Medical Team and admitted from Jan. 29, 2020 to Mar. 20, 2020 were included. The positive nucleic acid of COVID-19 virus and combination with hypertension, coronary heart disease or diabetes were in the standard. We collected the clinical data and laboratory examination results of the eligible patients to evaluate the related factors of death.Results: In the study, 94 COVID-19 patients enrolled were divided into the group of death (13 cases) and the group of survivors (81 cases), the average age was 66.7 years. Compared with the survival group, the death group had faster basal heart rate(103.2 beats/min vs. 88.4 beats /min, P=0.004), shortness of breath(29.0 beats /min vs. 20.0 beats /min, P<0.001), higher neutrophil count(9.2×109/L vs. 3.8×109/L, P<0.001), lower lymphocyte count(0.5×109/L vs. 1.1×109/L, P<0.001), creatine kinase MB(CK-MB, 3.2 μg/L vs. 0.8 μg/L, P<0.001), high sensitivity cardiac troponin Ⅰ(hs-cTnⅠ, 217.2 ng/L vs. 4.9 ng/L, P<0.001), N-terminal pro brain natriuretic peptide(NT-proBNP; 945.0 μg/L vs. 154.0 μg/L, P<0.001), inflammatory factor ferritin(770.2 μg/L vs. 622.8 μg/L , P=0.050), interleukin-2 recepter(IL-2R, 1 586.0 U/mL vs. 694.0 U/mL, P<0.001), interleukin-6(IL-6, 82.3 ng/L vs. 13.0 ng/L, P<0.001), interleukin-10(IL-10, 9.8 ng/L vs. 5.0 ng/L, P<0.001)were higher than those in the survival group. Univariate logistic regression analysis showed that the risk factors for death were old age, low non oxygen saturation, low lymphocyte count, myocardial injury, abnormal increase of IL 2R, IL-6, and IL-10. Multivariate regression showed that old age (OR=1.11, 95%CI=1.03-1.19, P=0.026), low non oxygen saturation(OR=0.85, 95%CI=0.72-0.99, P=0.041), and abnormal increase of IL-10(>9.1 ng/L, OR=101.93, 95%CI=4.74-2190.71, P=0.003)were independent risk factors for COVID-19 patients combined with hypertension, coronary heart disease or diabetes.Conclusion: In COVID-19 patients combined with hypertension, coronary heart disease or diabetes, the risk factors for death were old age, low non oxygen saturation, low lymphocyte count, myocardial injury, and abnormal increase of IL-2R, IL-6, and IL-10. Old age, low non oxygen saturation and abnormal increase of IL-10 were independent risk factors.

Key words: COVID-19, Hypertension, Coronary heart disease, Diabetes, Risk factors

CLC Number: 

  • R563.1

Table 1

Distribution of COVID-19 patients combined with hypertension, coronary heart disease or diabetes"

Items Death group
(n=13)
Survival group
(n=81)
Hypertension 7 47
Diabetes 2 3
CHD 0 6
Hypertension & diabetes 1 13
Hypertension & CHD 1 4
Diabetes & CHD 1 1
Hypertension & diabetes & CHD 1 7

Table 2

Demographic and baseline informations"

Items Death group(n=13) Survival group(n=81) t/Z/χ2 P
General information
Age/years, M(IQR) 77.0 (67.5, 83.0) 66.0 (59.0, 72.5) -2.894 0.731
Male, n(%) 8 (61.5) 37 (45.7) 1.129 0.288
Vital signs on admission
Heart rate/(beats/min), x?±s 103.2±15.8 88.4±16.7 2.997 0.004
Systolic pressure/mmHg, M(IQR) 135.0 (109.0, 161.5) 140.0 (125.0, 149.5) -0.526 0.599
Diastolic pressure (mmHg), x?±s 84.6±15.7 84.0±13.1 0.156 0.876
Respiratory rate/(beats/min), M(IQR) 29.0 (24.0, 30.0) 20.0 (20.0, 24.0) -3.689 <0.001
SpO2/%, M(IQR) 89.0 (78.5, 94.5) 96.0 (94.0, 98.0) -3.232 1.000
Complete blood count
WBC (×109/L), M(IQR) 10.2 (6.3, 14.7) 5.6 (4.5, 7.8) -3.242 1.000
Neutrophil (×109/L), M(IQR) 9.2 (5.5, 13.9) 3.8 (2.7, 5.9) -3.510 <0.001
Lymphocyte (×109/L), M(IQR) 0.5 (0.3, 0.7) 1.1 (0.7, 1.5) -3.719 <0.001
Creatinine/(μmol/L), M(IQR) 86.0 (73.5, 112.5) 74.0 (57.0, 92.0) -1.807 0.073
Biomarkers of myocardial injury
CK-MB/(μg/L), M(IQR) 3.2 (2.3, 6.9) 0.8 (0.5, 1.0) -4.196 <0.001
hs-cTNⅠ/(ng/L), M(IQR) 217.2 (34.4, 4037.4) 4.9 (2.5, 13.9) -4.513 <0.001
NT-proBNP/(μg/L), M(IQR) 945.0 (518.5, 3 464.0) 154.0 (75.0, 415.3) -4.111 <0.001
Myocardial injury, n(%) 10 (76.9) 13 (16.0) 22.461 <0.001
Cytokines
Ferritin/(μg/L), M(IQR) 770.2 (598.0, 2 172.0) 622.8 (385.3, 1 162.7) -2.180 0.050
IL-2R/(U/mL), M(IQR) 1 586.0 (1 253.0, 2 364.0) 694.0 (425.0, 1 054.5) -3.740 <0.001
IL-6/(ng/L), M(IQR) 82.3 (37.8, 164.8) 13.0 (4.0, 39.4) -3.960 <0.001
IL-8/(ng/L), M(IQR) 29.1 (16.2, 52.4) 12.4 (7.0, 21.3) -2.551 0.160
IL-10/(ng/L), M(IQR) 9.8 (6.8, 17.9) 5.0 (5.0, 5.5) -4.376 <0.001
TNF-α/(ng/L), M(IQR) 13.3 (7.2, 17.4) 8.8 (5.7, 12.3) -2.202 0.051

Table 3

Logistic regression analysis of factors of death"

Items Univariate analysis Multivariate analysis
OR(95%CI) P OR(95%CI) P
Age/years 1.11 (1.03, 1.19) 0.004 1.18 (1.02, 1.36) 0.026
Male 1.90 (0.57, 6.32) 0.293 0.16 (0.02, 1.55) 0.113
Hypertension (No vs. Yes) 0.47 (0.11, 2.00) 0.307
Diabetes (No vs. Yes) 1.48 (0.44, 5.00) 0.524
CHD (No vs. Yes) 1.05 (0.26, 4.23) 0.945
SpO2/% 0.89 (0.83, 0.96) 0.001 0.85 (0.72, 0.99) 0.041
Neutrophil (×109/L) 1.05 (0.98, 1.11) 0.155
Lymphocyte (×109/L) 0.03 (0.00, 0.30) 0.003
Creatinine/(μmol/L) 1.00 (0.99, 1.01) 0.897
Myocardial injury 17.44 (4.21, 72.1) <0.001 11.77 (0.93, 148.87) 0.057
Ferritin>400 μg/L 5.36 (0.66, 43.48) 0.116
IL-2R>710 U/mL 5.64 (1.18, 27.05) 0.031
IL-6>35 ng/L 8.40 (2.12, 33.33) 0.002
IL-8>62 ng/L 4.73 (0.71, 31.52) 0.109
IL-10>9.1 ng/L 14.60 (3.84, 55.46) <0.001 101.93 (4.74, 2 190.71) 0.003
TNF-α>8.1 ng/L 1.71 (0.49, 6.02) 0.402
[1] Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission[J]. Sci China Life Sci, 2020,63(3):457-460.
pmid: 32009228
[2] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020,395(10223):497-506.
doi: 10.1016/S0140-6736(20)30183-5 pmid: 31986264
[3] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study[J]. Lancet, 2020,395(10229):1054-1062.
pmid: 32171076
[4] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020, 2(2020-02-07)[2020-04-06]. https://jamanetwork.com/journals/jama/fullarticle/2761044.
[5] Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018)[J]. J Am Coll Cardiol, 2018,72(18):2231-2264.
[6] Chan JWM, Ng CK, Chan YH, et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)[J]. Thorax, 2003,58(8):686-689.
pmid: 12885985
[7] Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area[J]. JAMA, 2003,289(21):2801-2809.
pmid: 12734147
[8] Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis[J]. Int J Infect Dis, 2016,49:129-133.
[9] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell, 2020,181(2):271-280.
doi: 10.1016/j.cell.2020.02.052 pmid: 32142651
[10] Hamming I, Timens W, Bulthuis M, et al. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis[J]. J Pathol, 2004,203(2):631-637.
[11] Keidar S, Kaplan M, Gamliellazarovich A, et al. ACE2 of the heart: From angiotensin Ⅰ to angiotensin (1-7)[J]. Cardiovasc Res, 2007,73(3):463-469
pmid: 17049503
[12] Clerkin KJ, Fried JA, Raikhelkar J, et al. Corona virus disease 2019 (COVID-19) and cardiovascular disease[J]. Circulation, 2020, 3(2020-03-21)[2020-04-07]. https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.120.046941.
[13] Guan W, Ni Z, Hu Y, et al. Clinical characteristics of corona virus disease 2019 in China[J]. N Engl J Med, 2020,382(18):1708-1720.
[14] Hu H, Ma F, Wei X, et al. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin[J]. Eur Heart J, 2020, (2020-03-16)[2020-04-08]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184348.
pmid: 32562486
[15] Sala S, Peretto G, Gramegna M, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection[J] Eur Heart J, 2020, 4(2020-04-08)[2020-04-10]. https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa286/5817735.
[16] Chen Z, Hu Y, Xiong T, et al. IL-10 promotes development of acute respiratory distress syndrome via inhibiting differentiation of bone marrow stem cells to alveolar type 2 epithelial cells[J]. Eur Rev Med Pharmacol Sci, 2018,22:6085-6092.
[17] Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology[J]. Semin Immunopathol, 2017,39(5):529-539.
[18] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020,395(10223):507-513.
doi: 10.1016/S0140-6736(20)30211-7 pmid: 32007143
[19] Watts ER, Walmsley SR. Inflammation and Hypoxia: HIF and PHD Isoform Selectivity[J]. Trends Mol Med, 2019,25(1):33-46.
[20] Campbell EL, Bruyninckx WJ, Kelly CJ, et al. Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation[J]. Immunity, 2014,40(1):66-77.
[1] Zhicun LI, Tianyu WU, Lei LIANG, Yu FAN, Yisen MENG, Qian ZHANG. Risk factors analysis and nomogram model construction of postoperative pathological upgrade of prostate cancer patients with single core positive biopsy [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 896-901.
[2] Peiheng ZHANG, Ying GAO, Honghua WU, Jian ZHANG, Junqing ZHANG. Fulminant type 1 diabetes mellitus with acute pancreatitis: A case report and literature review [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 923-927.
[3] Ye YAN,Xiaolong LI,Haizhui XIA,Xuehua ZHU,Yuting ZHANG,Fan ZHANG,Ke LIU,Cheng LIU,Lulin MA. Analysis of risk factors for long-term overactive bladder after radical prostatectomy [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 589-593.
[4] Yan CHEN,Kuangmeng LI,Kai HONG,Shudong ZHANG,Jianxing CHENG,Zhongjie ZHENG,Wenhao TANG,Lianming ZHAO,Haitao ZHANG,Hui JIANG,Haocheng LIN. Retrospective study on the impact of penile corpus cavernosum injection test on penile vascular function [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 680-686.
[5] Bo PANG,Tongjun GUO,Xi CHEN,Huaqi GUO,Jiazhang SHI,Juan CHEN,Xinmei WANG,Yaoyan LI,Anqi SHAN,Hengyi YU,Jing HUANG,Naijun TANG,Yan WANG,Xinbiao GUO,Guoxing LI,Shaowei WU. Personal nitrogen oxides exposure levels and related influencing factors in adults over 35 years old in Tianjin and Shanghai [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 700-707.
[6] Jing HE,Zhongze FANG,Ying YANG,Jing LIU,Wenyao MA,Yong HUO,Wei GAO,Yangfeng WU,Gaoqiang XIE. Relationship between lipid metabolism molecules in plasma and carotid atheroscle-rotic plaques, traditional cardiovascular risk factors, and dietary factors [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 722-728.
[7] Shan CAI,Yihang ZHANG,Ziyue CHEN,Yunfe LIU,Jiajia DANG,Di SHI,Jiaxin LI,Tianyu HUANG,Jun MA,Yi SONG. Status and pathways of factors influencing physical activity time among elementary and junior high school students in Beijing [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 403-410.
[8] Zuhong ZHANG,Tianjiao CHEN,Jun MA. Associations between puberty timing and cardiovascular metabolic risk factors among primary and secondary students [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 418-423.
[9] Yuting LIN,Huali WANG,Yu TIAN,Litong GONG,Chun CHANG. Factors influencing cognitive function among the older adults in Beijing [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 456-461.
[10] Jinrong ZHU,Yana ZHAO,Wei HUANG,Weiwei ZHAO,Yue WANG,Song WANG,Chunyan SU. Clinical characteristics of COVID-19 infection in patients undergoing hemodialysis [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 267-272.
[11] Zhanhong LAI,Jiachen LI,Zelin YUN,Yonggang ZHANG,Hao ZHANG,Xiaoyan XING,Miao SHAO,Yuebo JIN,Naidi WANG,Yimin LI,Yuhui LI,Zhanguo LI. A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 284-292.
[12] Xiaoqian SI,Xiujuan ZHAO,Fengxue ZHU,Tianbing WANG. Risk factors for acute respiratory distress syndrome in patients with traumatic hemorrhagic shock [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 307-312.
[13] Xin LIU,Xueying SHI,Jun LI. A case of COVID-19 associated ischemic colitis [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 362-365.
[14] Yangyang LI,Lin HOU,Zijun MA,Shanyamei HUANG,Jie LIU,Chaomei ZENG,Jiong QIN. Association of pregnancy factors with cow's milk protein allergy in infants [J]. Journal of Peking University (Health Sciences), 2024, 56(1): 144-149.
[15] Yujia MA,Ranli LU,Zechen ZHOU,Xiaoyi LI,Zeyu YAN,Yiqun WU,Dafang CHEN. Association between insomnia and type 2 diabetes: A two-sample Mendelian rando-mization study [J]. Journal of Peking University (Health Sciences), 2024, 56(1): 174-178.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!